| CLX |
Report |
Q4 Gross Margin (GAAP) |
IN-LINE |
pred ~42.5% vs. cons ~42.6% |
MEDIUM |
| CLX |
Report |
Q4 Organic Sales Growth |
IN-LINE |
pred ~flat/-1% vs. cons ~flat |
MEDIUM |
| CLX |
Report |
Q4 Adj. EPS |
BEAT |
pred ~$1.75 vs. cons $1.69 |
MEDIUM |
| CLX |
Guide |
FY27 Adj. EPS (FY2027) |
LOWER |
guide midpoint ~$5.80 vs. cons $5.92 |
MEDIUM |
| CLX |
Guide |
FY27 Organic Sales Growth (FY2027) |
LOWER |
guide ~3.5-4.5% vs. cons +4.6% |
MEDIUM |
| CLX |
Guide |
CEO Succession (qualitative) |
UNCHANGED |
no announcement; search ongoing; tone stable |
HIGH |
| CLX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
MEDIUM |
| CLX |
Return |
5-day cumulative residual |
-5.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH - sell-side cuts FY27 estimates as implied out-period math lands below consensus; short covering provides partial offset but does not reverse direction |
MEDIUM |